Dr. Marty Makary stepped down as the commissioner of the U.S. Food and Drug Administration on Tuesday, May 12, 2026 [1].
This departure leaves a leadership vacuum at one of the world's most influential regulatory agencies during a period of significant internal instability. The move signals a deepening crisis within the administration's health policy apparatus.
Makary left his post amid reports that he was about to be fired [2]. While some reports describe the move as a resignation, others indicate he was pushed out before President Donald Trump could formally dismiss him [3].
Internal tensions contributed to the exit, specifically a rift between Makary and the Medical Association of Health Administrators (MAHA) [4]. The friction between the commissioner and the association created a volatile environment at the agency's Washington, D.C., headquarters [5].
This exit marks the fourth high-profile departure from the administration in 2026 [6]. The recurring loss of top-tier officials suggests a pattern of instability within the current executive branch's management of federal agencies.
Makary's tenure was characterized by the friction that eventually led to his departure on May 12 [1]. The FDA now faces the challenge of appointing a successor who can bridge the gap between the administration's goals and the operational requirements of the agency [5].
“Dr. Marty Makary stepped down as the commissioner of the U.S. Food and Drug Administration on Tuesday.”
The departure of Dr. Makary underscores a growing misalignment between the administration's political appointees and the established health administrative structures. With four high-level exits this year, the FDA may struggle with continuity in drug approvals and public health oversight, potentially slowing the implementation of the administration's health agenda.
